Lam PY - Search Results

1

N-in-1 dosing pharmacokinetics in drug discovery: experience, theoretical and practical considerations.

He K, Qian M, Wong H, Bai SA, He B, Brogdon B, Grace JE, Xin B, Wu J, Ren SX, Zeng H, Deng Y, Graden DM, Olah TV, Unger SE, Luettgen JM, Knabb RM, Pinto DJ, Lam PY, Duan J, Wexler RR, Decicco CP, Christ DD, Grossman SJ. He K, et al. Among authors: lam py. J Pharm Sci. 2008 Jul;97(7):2568-80. doi: 10.1002/jps.21196. J Pharm Sci. 2008. PMID: 17914718

2

Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor.

He K, Luettgen JM, Zhang D, He B, Grace JE Jr, Xin B, Pinto DJ, Wong PC, Knabb RM, Lam PY, Wexler RR, Grossman SJ. He K, et al. Among authors: lam py. Eur J Drug Metab Pharmacokinet. 2011 Sep;36(3):129-39. doi: 10.1007/s13318-011-0037-x. Epub 2011 Apr 2. Eur J Drug Metab Pharmacokinet. 2011. PMID: 21461793

3

Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants.

Lam PY, Clark CG, Li R, Pinto DJ, Orwat MJ, Galemmo RA, Fevig JM, Teleha CA, Alexander RS, Smallwood AM, Rossi KA, Wright MR, Bai SA, He K, Luettgen JM, Wong PC, Knabb RM, Wexler RR. Lam PY, et al. J Med Chem. 2003 Oct 9;46(21):4405-18. doi: 10.1021/jm020578e. J Med Chem. 2003. PMID: 14521405

4

Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors.

Quan ML, Han Q, Fevig JM, Lam PY, Bai S, Knabb RM, Luettgen JM, Wong PC, Wexler RR. Quan ML, et al. Among authors: lam py. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1795-8. doi: 10.1016/j.bmcl.2006.01.010. Epub 2006 Jan 24. Bioorg Med Chem Lett. 2006. PMID: 16434195

5

Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa.

Fevig JM, Cacciola J, Buriak J Jr, Rossi KA, Knabb RM, Luettgen JM, Wong PC, Bai SA, Wexler RR, Lam PY. Fevig JM, et al. Among authors: lam py. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3755-60. doi: 10.1016/j.bmcl.2006.04.044. Epub 2006 May 8. Bioorg Med Chem Lett. 2006. PMID: 16682200

6

Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues.

Qiao JX, Cheng X, Smallheer JM, Galemmo RA, Drummond S, Pinto DJ, Cheney DL, He K, Wong PC, Luettgen JM, Knabb RM, Wexler RR, Lam PY. Qiao JX, et al. Among authors: lam py. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1432-7. doi: 10.1016/j.bmcl.2006.11.071. Epub 2006 Dec 1. Bioorg Med Chem Lett. 2007. PMID: 17174550

7

Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications.

Qiao JX, Wang TC, Wang GZ, Cheney DL, He K, Rendina AR, Xin B, Luettgen JM, Knabb RM, Wexler RR, Lam PY. Qiao JX, et al. Among authors: lam py. Bioorg Med Chem Lett. 2007 Sep 15;17(18):5041-8. doi: 10.1016/j.bmcl.2007.07.020. Epub 2007 Jul 13. Bioorg Med Chem Lett. 2007. PMID: 17643988

8

Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.

Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, Wong PC, Rendina AR, Luettgen JM, Knabb RM, He K, Xin B, Wexler RR, Lam PY. Pinto DJ, et al. Among authors: lam py. J Med Chem. 2007 Nov 1;50(22):5339-56. doi: 10.1021/jm070245n. Epub 2007 Oct 3. J Med Chem. 2007. PMID: 17914785

9

Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: discovery of novel, highly potent inhibitors of Factor Xa.

Qiao JX, Cheney DL, Alexander RS, Smallwood AM, King SR, He K, Rendina AR, Luettgen JM, Knabb RM, Wexler RR, Lam PY. Qiao JX, et al. Among authors: lam py. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4118-23. doi: 10.1016/j.bmcl.2008.05.095. Epub 2008 May 29. Bioorg Med Chem Lett. 2008. PMID: 18550370

10

Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.

Orwat MJ, Qiao JX, He K, Rendina AR, Luettgen JM, Rossi KA, Xin B, Knabb RM, Wexler RR, Lam PY, Pinto DJ. Orwat MJ, et al. Among authors: lam py. Bioorg Med Chem Lett. 2014 Aug 1;24(15):3341-5. doi: 10.1016/j.bmcl.2014.05.101. Epub 2014 Jun 7. Bioorg Med Chem Lett. 2014. PMID: 24951330

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

274 results

Search Page

Filters